Cargando...
Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?
Recent phase II and III studies with intravenous immunoglobulin (IVIG) in patients with Alzheimer’s disease (AD) did not find evidence for the slowing of AD progression compared to placebo-treated patients, in contrast to encouraging results in pilot studies. An additional phase III trial is ongoing...
Gardado en:
| Publicado en: | J Neuroinflammation |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BioMed Central
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4265363/ https://ncbi.nlm.nih.gov/pubmed/25476011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12974-014-0198-z |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|